Clinical Trials Logo

Gastroesophageal Junction Cancer clinical trials

View clinical trials related to Gastroesophageal Junction Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05233436 Terminated - Gastric Cancer Clinical Trials

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Start date: February 24, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate the clinical activity of monotherapy and combination; and select the recommended dose of PF-07265028 monotherapy and in combination for potential further studies and development. The study contains 2 parts, Dose Escalation (Part 1) to determine the recommended dose of PF-07265028 as single agent and in combination, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose. It is expected that most participants will take part in this study for up to 1 year with six on-site visits in the first month and then at least twice every subsequent month while they are on treatment.

NCT ID: NCT04510285 Terminated - Gastric Cancer Clinical Trials

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Start date: August 10, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether treatment with trastuzumab combined with pembrolizumab will improve the clearance of tumor DNA from participants' bodies after surgery.

NCT ID: NCT02726399 Terminated - Gastric Cancer Clinical Trials

Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

Start date: March 18, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare any good and bad effects of using ramucirumab along with the usual trastuzumab and chemotherapy to using the usual chemotherapy and trastuzumab alone.

NCT ID: NCT01813253 Terminated - Gastric Cancer Clinical Trials

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Start date: May 13, 2013
Phase: Phase 3
Study type: Interventional

This study will evaluate overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.

NCT ID: NCT01774851 Terminated - Stomach Cancer Clinical Trials

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Start date: January 2013
Phase: Phase 2
Study type: Interventional

To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone